ESR1 and breast carcinoma: Starting from two breast cancer cell lines, one estrogen receptor positive and one estrogen receptor negative, using increasing concentrations of paclitaxel and doxorubicin we parallel developed 29 cell lines to establish a model similar to the evolution of the acquired drug resistance.